Cantex Pharmaceuticals, Inc. is a clinical stage pharmaceutical company developing novel, well-tolerated, oral treatments of cancer and other serious illnesses.
Cantex is led by Stephen Marcus, M.D., Neil Flanzraich and Juan Rodriguez; seasoned drug developers and pharmaceutical executives with stellar track records of developing blockbuster products and extensive transactional experience.
Azeliragon is a safe, once-daily oral medication in Phase 2/3 development that targets glioblastoma, metastatic brain tumors, pancreatic cancer, breast cancer, and prevention of acute kidney injury in hospitalized patients with pneumonia.
May 2024 – Cantex Pharmaceuticals announced that azeliragon, a well-tolerated once-a-day pill that inhibits “RAGE” (the receptor for advanced glycation end products), will be featured in four abstracts at this year’s 2024 ASCO Annual Meeting to be held in Chicago.
May 2024 – Cantex Pharmaceuticals announced that the FDA has granted Orphan Drug Designation to Cantex’ azeliragon, a well-tolerated once-a-day pill, for the treatment of pancreatic cancer. This new azeliragon orphan drug designation adds to azeliragon’s previous orphan drug designation for the treatment of glioblastoma, received in early 2023.
March 2024 – Cantex Pharmaceuticals announced that Stephen Marcus, M.D., Chief Executive Officer, will be an expert speaker at 5th Annual Glioblastoma Drug Development Summit, delivering a podium presentation titled, ““Delving into a Clinical Update on Azeliragon for GBM – Implementable Lessons for Small Molecule Success.”